Autologous HER2 CMV Bispecific CAR T Cells Are Safe and Demonstrate Clinical Benefit for Glioblastoma in a Phase I Trial.

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-o11
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy